logo

For the Inventor, By the Inventor

Pennington, NJ, United States of America

Yufen Zhao

This inventor holds 27 USPTO granted patents and 3 published patent applications and 13 EPO patents, primarily in Kinase Inhibitors. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2005-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yufen Zhao. Retrieved from https://idiyas.com/inventor/yufen-zhao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.1

ph-index = 4

Forward Citations = 133(Granted Patents)


Company Filing History:

goldMedal27 out of 3,742 
 
Bristol-Myers Squibb Compnay
 patents

Years Active: 2005-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Cyclic Dinucleotides
Kinase Inhibitors
Anticancer Agents
Imidazopyridazines
Benzodiazepinone Compounds
TGFβR Antagonists
Fused Heterocyclic Compounds
Acridone Inhibitors
Fluoroalkyl Compounds
Pyrrolotriazine Compounds
Nuclear Hormone Receptor Modulators
Imidazotriazinecarbonitriles
27 patents (USPTO):Explore Patents
1. 11660311 - Cyclic dinucleotides as anticancer agents (2023-05-30),
2. 11427610 - Cyclic dinucleotides as anticancer agents (2022-08-30),
3. 11339185 - Cyclic dinucleotides as anticancer agents (2022-05-24),
4. 10744150 - Cyclic dinucleotides as anticancer agents (2020-08-18),
5. 10519187 - Cyclic dinucleotides as anticancer agents (2019-12-31),
6. 9708316 - TGFβR antagonists (2017-07-18),
7. 9556178 - Imidazotriazinecarbonitriles useful as kinase inhibitors (2017-01-31),
8. 9492460 - Carbazole compounds useful as bromodomain inhibitors (2016-11-15),
9. 9427442 - Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds (2016-08-30),
10. 9371328 - Imidazopyridazinecarbonitriles useful as kinase inhibitors (2016-06-21),
11. 9273057 - Imidazotriazinecarbonitriles useful as kinase inhibitors (2016-03-01),
12. 9273014 - Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof (2016-03-01),
13. 9242941 - Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds (2016-01-26),
14. 8999918 - Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof (2015-04-07),
15. 8940736 - Imidazotriazinecarbonitriles useful as kinase inhibitors (2015-01-27),

Title: Yufen Zhao: Innovator and Inventor in Cancer Research

Introduction

Yufen Zhao, located in Pennington, NJ, has made significant contributions to the field of cancer research through his innovative work. With an impressive portfolio of 27 patents, Zhao has focused on developing novel therapeutic solutions that address critical health challenges. His contributions underscore the vital role inventors play in advancing medical science and improving patient outcomes.

Latest Patents

Among Yufen Zhao's recent patents is his work on "Cyclic dinucleotides as anticancer agents." This invention is directed towards compounds characterized by a specific formula, which includes various defined substituents. The invention also encompasses pharmaceutically acceptable compositions containing these compounds, as well as methods to utilize these compositions in treating various disorders. The potential of these compounds may pave the way for new treatment avenues in oncology.

Career Highlights

Yufen Zhao is currently associated with Bristol-Myers Squibb Company, where he applies his expertise to develop cutting-edge solutions in the pharmaceutical industry. His extensive experience and accumulation of patents reflect his commitment to enhancing cancer therapies and improving patient care on a global scale.

Collaborations

Zhao collaborates with notable colleagues, including Brian E. Fink and Ashvinikumar V. Gavai. Together, they contribute to the research and development efforts at Bristol-Myers Squibb, pushing the boundaries of scientific knowledge and innovation.

Conclusion

Yufen Zhao exemplifies the spirit of innovation within the field of cancer research. His dedication to creating effective treatments and his robust patent portfolio demonstrate the importance of inventors in driving advancements in medicine. As he continues his work at Bristol-Myers Squibb, Zhao remains a pivotal figure in the ongoing pursuit of revolutionary healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…